The US Supreme Court has denied certiorari for the generic version of Tamiflu (Oseltamivir Phosphate) oral capsules. It is indicated for treatment of influenza.
The development saw the company’s scrip gaining 5.81 per cent to close the day at Rs. 1,642.80 on the BSE.
Hyderabad-based Natco Pharma partners with Alvogen for marketing of this product in the US.
The denial was issued on Monday in the case of Gilead Sciences Inc, Natco informed the BSE on Tuesday.
Certiorari is a writ seeking judicial review. It is issued by a superior court, directing an inferior court, tribunal or other public authority to send the record of a proceeding for review.
By Dr. Manjiri Somashekhar, Lead & Senior Consultant - Paediatric Surgery, Aster Women and Children…
Mumbai, June 01, 2024: As part of its CSR effort, NTPC Ltd launches a major cancer…
By Dr. Priyanka Kuri, Consultant – Dermatology, Aster Whitefield Hospital, Bengaluru Do you think that…
Nagpur, May 23, 2024: The Intensivist and Critical Care team of American Oncology Institute (AOI) at…
Mumbai, May 22, 2024: The Department of Nursing at S.L. Raheja Hospital, Mahim - A…
Hubli, May 20, 2024: In a significant move to support child nutrition through effective logistical contributions,…